Fig. 7: SB-therapy induces Breg and Tr1 cell generation.

An AR mouse model was prepared as described in Fig. 6. Single cells were isolated from the nasal mucosal tissues and analyzed by FACS, RT-qPCR, and western blotting. a, b Gated FACS plots show IL-10⁺ B cell (B10) counts. Dot plots show B10 cell frequency. Dot plots show integrated density of immunoblots. c, d B cells were isolated from the nasal tissues, and analyzed by western blotting. Immunoblots show phosphorylated GSK3 levels. Scatter plots show integrated density of immunoblots. e CD3⁺ CD4⁺ T cells were gated. f Gated FACS plots show Tr1 cell counts (the LAG3⁺ IL-10⁺ cells were also CD49b⁺, not shown). g Scatter dot plots show Tr1 cell frequency. The data of b, e are presented as mean ± SD. ***p < 0.001 (ANOVA followed by the Bonferroni post hoc test), compared with the NS-treated AR group. Each dot presents data obtained from one mouse. Each group consists of six mice. The data of a, c, e, f are from one experiment, that represent three independent experiments. SBi: Mice were treated with both SB and IL-10 inhibitor AS101 (the “i” stands for “inhibitor”). Final concentration in nasal instillation: AS101 = 1 mg/ml; SB = 1 mg/ml).